Building A Cancer Pipeline In A Molecule With Actuate Therapeutics' Dan Schmitt
Streams straight from the publisher. podnod never proxies or re-hosts episode audio.
We love to hear from our listeners. Send us a message.
On this week's episode of the Business of Biotech, Dan Schmitt, President and CEO at Actuate Therapeutics, talks about building a company around elraglusib, a GSK-3β inhibitor for cancer. Dan describes his fast-fail approach to early product testing and development, using basket trials to evaluate chemotherapy combinations, and choosing pancreatic cancer as a lead program. He also talks about surviving an IPO during a brutal funding cycle for biotech, building lean teams and efficient operations, and potentially onshoring API in response to changing U.S. policy.
Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.
Subscribe to our monthly Business of Biotech newsletter.
Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com
Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/
We love to hear from our listeners. Send us a message.
buzzsprout.comBusiness of Biotech
lifescienceleader.comBusiness of Biotech newsletter
www9.lifescienceleader.comhttps://www.linkedin.com/in/bencomer/
linkedin.com
- 0:00Meet Dan Schmidt And Actuate
- 1:16From Vet Clinic Roots To Big Pharma
- 5:28Scouting Academia For Spinouts
- 9:31Founding Actuate Around GSK3 Inhibitors
- 13:05Proving The Molecule Across Many Labs
- 16:26Why Pancreatic Cancer As Lead
- 20:12Safety, Specificity, And Mechanism
- 24:06The Unmet Need In Pancreatic Cancer
- 28:05Single Asset Strategy Pros And Cons
- 30:26Weathering A Brutal IPO Market
- 34:00Running Lean And Funding Smart
- 38:08Partnerships, CDMOs, And Supply Resilience
- 41:46Policy, Onshoring, And Risk Planning
- 44:59FDA Outlook And Survival Endpoints
- 48:10Market Green Shoots And Momentum
- 50:35Near-Term Milestones And What’s Next